The Safety of Melatonin in Humans

Andersen, Lars Peter Holst; Gögenur, Ismail; Rosenberg, Jacob; Reíter, Russel J.

doi:10.1007/s40261-015-0368-5

Cited by 359 publications

(270 citation statements)

References 65 publications

Supporting

Mentioning

226

Contrasting

Unclassified

Order By: Relevance

“…Melatonin also appeared effective in different neonatal pathological conditions, including neonatal sepsis, bronchopulmonary dysplasia, and neonatal asphyxia [16,17]. Because of its pleiotropic effects, safety [18], and favorable pharmacokinetic profile in neonates [19], melatonin has been proposed as an adjunctive therapy to hypothermia in perinatal HIE.…”

Section: Introductionmentioning

confidence: 99%

Melatonin Acts in Synergy with Hypothermia to Reduce Oxygen-Glucose Deprivation-Induced Cell Death in Rat Hippocampus Organotypic Slice Cultures

et al. 2018

View full text Add to dashboard Cite

Background: Hypoxic-ischemic encephalopathy is a major cause of neonatal morbidity. Therapeutic hypothermia, while beneficial, still leaves many treated infants with lifelong disabilities. Thus, adjunctive therapies, such as melatonin, are needed to provide additional neuroprotection. Objectives: The aim of this study was to determine a range of melatonin concentrations that could result in neuroprotective synergy with hypothermia. Methods: Hypoxia-ischemia was simulated by transient oxygen-glucose deprivation (OGD) in organotypic hippocampal slice cultures derived from neonatal rats. Cell damage was quantified by propidium iodide (PI) labeling. Results: Melatonin reduced OGD- induced cell death in a concentration-dependent manner (1–100 μM) with an EC₅₀ of about 25 μM. Hypothermia attenuated cell death in a time-dependent manner, with a nearly full protection upon 24-h exposure (78%) and partial protection (40%) upon 6-h exposure. When submaximal effective concentrations of melatonin (25 or 50 μM, resulting in 54 and 64% protection) were combined with 6 h of hypothermia, nearly full protection (73 and 78%, respectively; p < 0.05 and p < 0.01) was observed. Conclusion: Melatonin acts in synergy with hypothermia in attenuating OGD-induced damage in organotypic hippocampal cultures. This reductionist approach allows the determination of a range of concentrations of melatonin capable of enhancing hypothermic neuroprotection. This information, coupled with pharmacokinetic data, will help to define the therapeutic dosage of melatonin in vivo and, ultimately, in patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Melatonin Acts in Synergy with Hypothermia to Reduce Oxygen-Glucose Deprivation-Induced Cell Death in Rat Hippocampus Organotypic Slice Cultures

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Кроме этого, продолжительный прием мелатонина также не вызывает никаких опасений в отношении развития нежелательных реакций. Так, при применении мелатонина на протяжении 6 месяцев паци-ентами с мигренью и пациентами с нарушением сна риск развития побочных эффектов не возрастает [25,[53][54][55]. Для мигрени наиболее вероятная минимальная эффек-тивная доза у взрослых составляет 3-4 мг [22,25].…”

Section: Discussionunclassified

The Role of Melatonin in the Treatment of Chronic Headache

Курганова¹,

Данилов²

2018

Med. sov.

View full text Add to dashboard Cite

Мелатонин -эндогенный хронобиотик, продемонстрировавший в ряде экспериментальных и клинических работ свои аналь-гетические возможности. Он оказался эффективен при фибромиалгии, синдроме раздраженного кишечника, боли в спине и различных типах головной боли. Наиболее высокий уровень доказательности анальгетических свойств мелатонина при мигрени и кластерной головной боли. В данном обзоре рассмотрены основные работы, имеющиеся на данный момент, где мелатонин используется при первичных головных болях различного типа. Обсуждаются возможные механизмы реализации мелатонином анальгетического действия и перспективы его использования в комплексной терапии головной боли.

show abstract

“…Taking into account the safety of melatonin [36], this molecule should be considered in the prevention of consequences of smoking, not only in postmenopausal women, but also in the whole population.…”

Section: Discussionmentioning

confidence: 99%

Melatonin reverses the enhanced oxidative damage to membrane lipids and improves skin biophysical characteristics in former-smokers – A study in postmenopausal women

Sagan¹,

Stępniak²,

Gesing³

et al. 2017

Ann Agric Environ Med.

View full text Add to dashboard Cite

reverses the enhanced oxidative damage to membrane lipids and improves skin biophysical characteristics in former-smokers -A study in postmenopausal women. Ann Agric Environ Med. 2017; 24(4): 659-666. doi: 10.5604/12321966.1235174 Abstract Introduction and objective. Protective antioxidative effects of melatonin have been repeatedly documented in experimental and clinical studies. One of the most spectacular exogenous prooxidative agents is cigarette smoking. The aim of the study was to evaluate the level of oxidative damage to membrane lipids (lipid peroxidation; LPO) in blood serum, and in epidermis exfoliated during microdermabrasion collected from former-smokers who were treated with melatonin. Materials and Method. The study was performed in postmenopausal women. Ninety (90) female volunteers, aged 46-67 years, were enrolled. Two major groups, i.e. never-smokers (n=44) and former-smokers (n=46), were divided into: Control, melatonin topical skin application, Restructurer (containing antioxidants) topical skin application, and melatonin oral treatment. Microdermabrasion was performed at point '0', after 2 weeks, and after 4 weeks of treatment. The following parameters were measured: LPO in blood serum, LPO in epidermis exfoliated during microdermabrasion, and skin biophysical characteristics, such as sebum, moisture, elasticity, and pigmentation. Malondialdehyde+4-hydroxyalkenals level (LPO index) was measured spectrophotometrically. Results. Melatonin oral treatment significantly reversed the increased serum LPO level in former-smokers already after 2 weeks of treatment. In a univariate regression model, LPO blood level constituted the only independent factor negatively associated with melatonin oral treatment. After 4 weeks of treatment, melatonin given orally increased skin sebum, moisture and elasticity levels, and melatonin applied topically increased sebum level. Conclusion. Exogenous melatonin reverses the enhanced oxidative damage to membrane lipids and improves skin biophysical characteristics in former-smokers.

show abstract

The Safety of Melatonin in Humans

Cited by 359 publications

References 65 publications

Melatonin Acts in Synergy with Hypothermia to Reduce Oxygen-Glucose Deprivation-Induced Cell Death in Rat Hippocampus Organotypic Slice Cultures

Melatonin Acts in Synergy with Hypothermia to Reduce Oxygen-Glucose Deprivation-Induced Cell Death in Rat Hippocampus Organotypic Slice Cultures

The Role of Melatonin in the Treatment of Chronic Headache

Melatonin reverses the enhanced oxidative damage to membrane lipids and improves skin biophysical characteristics in former-smokers – A study in postmenopausal women

Contact Info

Product

Resources

About